CRA was retained to develop a technology strategy to support improvements in drug discovery and development productivity. We profiled the company’s existing technology positions and assessed technology opportunities for its future. We created strategy options, supporting them with insights into technology and supplier evolution, and we considered how they could adopt new technology. Finally, CRA supported the key implementation decisions to divest existing technology, license/acquire new technology and monitor/experiment with emerging technology
Supply chain management in the AI era: A vision statement from the operations management community
CRA’s Maxime Cohen is a contributor to the academic and industry leader team releasing the vision statement “Supply Chain Management in the AI era: A Vision...